We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $3.18 · 13 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Lawyers take third shot at approval for $32m GoodRx privacy settlement in US - MLex
Lawyers take third shot at approval for $32m GoodRx privacy settlement in US MLex
GoodRx launches affordable subscription plan - BioXconomy
GoodRx launches affordable subscription plan BioXconomy
GoodRx Launches subscription for savings - Naples Daily News
GoodRx Launches subscription for savings Naples Daily News
New 'GoodRx Companion' subscription targets rising costs - Naples Daily News
New 'GoodRx Companion' subscription targets rising costs Naples Daily News
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $3.5 - Moomoo
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $3.5 Moomoo
GoodRx (NASDAQ: GDRX) director receives 4,642 deferred stock units - Stock Titan
GoodRx (NASDAQ: GDRX) director receives 4,642 deferred stock units Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $0.08 | — | — | $193.16M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.03 | — | — | $202.97M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.02 | — | — | $593.74M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.01 | — | — | $398.49M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 15. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 05. 12. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 03. 05. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 03. 04. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 03. 03. | Goldman Sachs | — | Maintain | Neutral → Neutral | — | Goldman Sachs: Neutral |
| 2026. 02. 28. | Mizuho | — | Maintain | Neutral → Neutral | — | Mizuho: Neutral |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.